

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GADICKE ANSBERT</u> _____ (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET _____ (Street) CAMBRIDGE MA 02142 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/23/2020	3. Issuer Name and Ticker or Trading Symbol <u>iTeos Therapeutics, Inc. [ITOS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(1)	Common Stock	1,269,230 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(1)	I	Footnote ⁽⁶⁾
Series B Preferred Stock	(1)	(1)	Common Stock	84,655 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(1)	I	Footnote ⁽⁷⁾
Series B Preferred Stock	(1)	(1)	Common Stock	43,687 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(1)	I	Footnote ⁽⁸⁾
Series B Preferred Stock	(1)	(1)	Common Stock	801,619 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(1)	I	Footnote ⁽⁹⁾
Series B Preferred Stock	(1)	(1)	Common Stock	42,605 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(1)	I	Footnote ⁽¹⁰⁾
Series B Preferred Stock	(1)	(1)	Common Stock	15,820 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(1)	I	Footnote ⁽¹¹⁾
Series B Preferred Stock	(1)	(1)	Common Stock	1,397,574 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(1)	I	Footnote ⁽¹²⁾
Series B-2 Preferred Stock	(13)	(13)	Common Stock	724,702 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(13)	I	Footnote ⁽⁶⁾
Series B-2 Preferred Stock	(13)	(13)	Common Stock	48,336 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(13)	I	Footnote ⁽⁷⁾
Series B-2 Preferred Stock	(13)	(13)	Common Stock	24,944 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(13)	I	Footnote ⁽⁸⁾
Series B-2 Preferred Stock	(13)	(13)	Common Stock	457,706 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(13)	I	Footnote ⁽⁹⁾
Series B-2 Preferred Stock	(13)	(13)	Common Stock	24,326 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(13)	I	Footnote ⁽¹⁰⁾
Series B-2 Preferred Stock	(13)	(13)	Common Stock	9,033 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(13)	I	Footnote ⁽¹¹⁾
Series B-2 Preferred Stock	(13)	(13)	Common Stock	797,983 ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	(13)	I	Footnote ⁽¹²⁾

1. Name and Address of Reporting Person* <u>GADICKE ANSBERT</u> _____ (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET _____ (Street)
--

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[UBS Oncology Impact Fund L.P.](#)

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[MPM Oncology Impact Management GP LLC](#)

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[MPM Oncology Impact Management LP](#)

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Oncology Impact Fund \(Cayman\) Management L.P.](#)

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

Explanation of Responses:

1. Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.

2. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.

3. (Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2

Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering.

4. (Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering.

5. (Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP ("UBS Oncology") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.

6. These securities are owned directly by MPM Bio Ventures 2014 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

7. These securities are owned directly by MPM Bio Ventures 2014 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

8. These securities are owned directly by MPM Asset Management Investors BV 2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

9. These securities are owned directly by MPM Bio Ventures 2018 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

10. These securities are owned directly by MPM Bio Ventures 2018 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

11. These securities are owned directly by MPM Asset Management Investors BV 2018 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

12. These securities are owned directly by UBS Oncology. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

13. Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.

Remarks:

* affiliated funds of Reporting Person

/s/ Ansbert Gadicke,
Ansbert Gadicke 07/23/2020

/s/ Ansbert Gadicke,
managing director of
MPM Oncology Impact
Management GP LLC, the
general partner of MPM
Oncology Impact
Management LP, the 07/23/2020
general partner of
Oncology Impact Fund
(Cayman) Management
L.P., the GP of UBS
Oncology Impact Fund
L.P.

/s/ Ansbert Gadicke,
managing director of
MPM Oncology Impact
Management GP LLC 07/23/2020

/s/ Ansbert Gadicke,
managing director of
MPM Oncology Impact
Management GP LLC, the 07/23/2020
general partner of MPM
Oncology Impact
Management LP

/s/ Ansbert Gadicke,
managing director of
MPM Oncology Impact
Management GP LLC, the
general partner of MPM
Oncology Impact 07/23/2020
Management LP, the
general partner of
Oncology Impact Fund
(Cayman) Management
L.P.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Michel Detheux, Matthew Call and Matthew Gall, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of iTeos Therapeutics, Inc. (the "Company"), (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the United States Securities and Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5, (iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each thereof, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D, Schedule 13G or any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney may be filed with the United States Securities and Exchange Commission as a confirming statement of the authority granted herein. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of July 23, 2020.

/s/ Ansbert Gadicke

Name: Ansbert Gadicke

